After 2 randomized clinical trials found it as safe and effective as the standard 3-drug regimen, the FDA approved the first 2-drug regimen for adults with HIV-1 who have never been treated with ART.
After 2 randomized clinical trials found it as safe and effective as the standard 3-drug regimen, the FDA approved the first 2-drug regimen for adults with HIV-1 who have never been treated with ART.
Following a clinical trial testing its safety and efficacy, the FDA has approved a new oral treatment for patients with relapsing forms of multiple sclerosis.
The new oral treatment for multiple sclerosis is indicated for patients with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The FDA has approved a new treatment option that is the first drug approved by the FDA specifically for the treatment of postpartum depression in adult women.
The FDA has approved a new treatment option that is the first drug approved by the FDA specifically for the treatment of postpartum depression in adult women.
